- Coronary heart disease. Situations where decreasing platelet aggregation tendency and reduction of blood clotting are indicated: in coronary heart disease, prevention of infarct complications, prophylaxis of secondary myocardial infarction.
Ingredients:
acetylsalicylic acid 75mg
Excipients:
microcrystalline cellulose, sodium starch glycolate, stearic acid orange lacquer.
Action
Acetylsalicylic acid administered to adults at doses of 30-75 mg / day inhibits platelet aggregation by reducing prostaglandin biosynthesis in platelets and vascular endothelial cells by irreversibly inhibiting cyclooxygenase synthesis, enzyme involved in the metabolism of peanut acid to PgG 2 and PgH 2 and thromboxane A 2 .
indications
Situations where reduction of platelet aggregation tendency and reduction of blood clotting are indicated: in ischemic heart disease, prevention of infarct complications, prophylaxis of secondary myocardial infarction and risk of sudden cardiac death. To prevent vascular congestion and stroke in patients with chronic atrial fibrillation.
Dosage
Adults: The first day of wysyceniowa dose of 150 mg. then 1 tabl. 50 mg or 75 mg daily depending on the condition of the patient.
Keywords. Coronary heart disease.